Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study.

Duong Thuy TranDavid B PreenKristjana EinarsdottirAnna Kemp-CaseyDeborah RandallLouisa R JormStephanie K Y ChoiAlys Havard

Published in: BMC medicine (2020)

Pregnancy exposure to smoking cessation pharmacotherapies does not appear to be associated with an increased risk of adverse birth outcomes. Lower risk of adverse birth outcomes in varenicline-exposed pregnancies is inconsistent with recommendations that NRT be used in preference to varenicline.

Keyphrases

smoking cessation
pregnancy outcomes
pregnant women
replacement therapy
gestational age
preterm birth
adverse drug
type diabetes
clinical practice
metabolic syndrome
adipose tissue
skeletal muscle